Here’s the RCT paper: “Muvalaplin, an Oral Small Molecule Inhibitor of Lipoprotein(a) Formation” by Stephen J. Nicholls, MBBS, PhD; Steven E. Nissen, MD; Cynthia Fleming, RN, MSN; et al.<p><a href="https://jamanetwork.com/journals/jama/fullarticle/2808864?guestAccessKey=ab2dcd1a-4075-4f27-a2f0-a4ed8251545f&linkId=231563292" rel="nofollow noreferrer">https://jamanetwork.com/journals/jama/fullarticle/2808864?gu...</a><p>“Oral doses of 30 mg to 800 mg for 14 days resulted in increasing muvalaplin plasma concentrations and half-life ranging from 70 to 414 hours. Muvalaplin lowered Lp(a) plasma levels within 24 hours after the first dose, with further Lp(a) reduction on repeated dosing. Maximum placebo-adjusted Lp(a) reduction was 63% to 65%, resulting in Lp(a) plasma levels less than 50 mg/dL in 93% of participants, with similar effects at daily doses of 100 mg or more.”